about
Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosaGut microbiota role in irritable bowel syndrome: New therapeutic strategiesDiscovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasisThe bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in miceProbiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activationThe bile acid receptor FXR is a modulator of intestinal innate immunityAspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammationCooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherenceMechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donorsEnhanced anti-inflammatory potency of a nitric oxide-releasing derivative of flunisolide: role of nuclear factor-kappaBDifferent sensitivity of lamina propria T-cell subsets to nitric oxide-induced apoptosis explains immunomodulatory activity of a nitric oxide-releasing derivative of mesalamine in rodent colitisDual COX-inhibitors: the answer is NO?Lipoxins in gastric mucosal health and diseaseInhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugsPotential cardioprotective actions of no-releasing aspirinNCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial functionCyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damageNCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxideGastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic studyGastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesisRelative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirinNO-NSAIDs: from inflammatory mediators to clinical readoutsA magic bullet for mucosal protection...and aspirin is the trigger!Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirinNitric oxide regulates immune cell bioenergetic: a mechanism to understand immunomodulatory functions of nitric oxide-releasing anti-inflammatory drugsHydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammationNitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins,Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular toneCo-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans
P50
Q24685768-AA049967-5E9D-4B61-B83F-027C62568B5EQ26768550-BA1E0617-063E-43DA-9D70-A0D0D1DC6D2EQ27309876-B00E1E6E-FD98-4EC1-8ABE-A0EDAF0BBE3DQ27318414-E31FA358-7304-4594-809F-86904878513BQ27327276-EA76B58F-EDE5-4309-B985-A51BED11F69AQ28116925-E41DB5D6-A785-46F7-A35A-424408407D09Q28166417-07A55AD7-C0C2-47D1-80DF-946286D8D58DQ28167148-47DC430B-E8F2-433C-9064-AF1CF39D062CQ28168049-76A764C1-2E6A-457A-9191-090B7004FF2FQ28168528-ED4DE198-32B2-49CA-B9D7-BF03DC57F6DFQ28175304-C7ABC734-8DE7-4F8A-BA63-4CEBB77ED64DQ28181577-CBAF7A4F-70C1-42AD-8027-C5DE462D0223Q28184246-A2BDFA0E-4685-4EF7-BD10-CA80B9746B67Q28192729-254BE813-3D3A-4482-B066-84C394BA1336Q28193422-670CC30F-4C6F-4D08-8B66-CE2E98FBCBA2Q28193668-423346A3-C29A-4B71-8AE7-5E551F84504EQ28194059-C9E8261C-18CF-4679-AAED-6A0C263724A0Q28194411-BDB55106-99C0-4148-BB12-2D6D1BBEA5B8Q28195152-7CC9E44C-7AD4-4CC8-9637-8F883B406E1EQ28195376-ED05F11B-B80B-4EC1-8413-217F22F71D4EQ28195729-01CA78F8-9DC6-404B-A014-CD8465A085FDQ28196549-E357491B-B873-4851-8271-9924BC821D11Q28196793-5F5DBE56-8CEA-4B10-9AD8-F1612E321CDAQ28196895-C3680801-BF28-4802-8A0B-5C5F14F977AFQ28199001-7E8BF5AD-C0C6-41C6-86FD-74D39122CB54Q28200154-CE425DA9-D9DE-4F89-BB36-535820F0F261Q28210271-9C54B94F-5263-4902-85BF-C9F863775FD5Q28211483-135C03C7-54BF-4F9F-BE07-05D595F0C1EFQ28212636-0351DE13-3B09-403F-BB41-1DA3D7DE3A6F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Stefano Fiorucci
@ast
Stefano Fiorucci
@en
Stefano Fiorucci
@es
Stefano Fiorucci
@sl
type
label
Stefano Fiorucci
@ast
Stefano Fiorucci
@en
Stefano Fiorucci
@es
Stefano Fiorucci
@sl
prefLabel
Stefano Fiorucci
@ast
Stefano Fiorucci
@en
Stefano Fiorucci
@es
Stefano Fiorucci
@sl